Glycans, complex carbohydrates attached to proteins and lipids, represent one of the most abundant and diverse classes of biomolecules in living organisms. Glycosylation, the enzymatic process by which glycans are attached to their target molecules, profoundly influences protein folding, stability, trafficking, and function. Alterations in glycosylation patterns have been documented in virtually every major disease category, from cancer to cardiovascular disease to autoimmune disorders.

Despite their biological importance, glycans have received less attention than genes, transcripts, and proteins in biomedical research. This "glyco-gap" reflects historical challenges in glycan analysis, including structural complexity, lack of amplification methods analogous to PCR, and the non-templated nature of glycan biosynthesis. However, recent technological advances are closing this gap, enabling large-scale glycomics studies that parallel developments in genomics and proteomics.

Mass spectrometry has emerged as the workhorse technology for glycomics, enabling sensitive and specific detection of glycan structures. Liquid chromatography separation coupled with mass spectrometry allows comprehensive profiling of glycans from biological samples. Nuclear magnetic resonance spectroscopy provides detailed structural information for specific glycan species. lectin-based methods and glycan arrays enable high-throughput screening of glycan-protein interactions.

Cohort studies incorporating glycomics have revealed striking associations between glycan patterns and disease states. In cancer, altered glycosylation is recognized as a hallmark of malignant transformation. Truncated O-glycans, increased branching of N-glycans, and altered sialylation patterns have been documented across multiple cancer types. These changes influence tumor cell adhesion, migration, immune evasion, and response to therapy.

Cardiovascular disease has also been linked to specific glycan signatures. Immunoglobulin G (IgG) glycosylation patterns, in particular, have emerged as biomarkers of cardiovascular risk. IgG molecules with reduced galactosylation are associated with increased inflammation and higher risk of cardiovascular events. These findings suggest that glycan patterns may capture aspects of disease risk not reflected by traditional biomarkers.

Autoimmune and inflammatory diseases show characteristic glycan alterations that may contribute to disease pathogenesis. In rheumatoid arthritis, changes in IgG glycosylation precede clinical disease onset, suggesting potential utility for early diagnosis. In inflammatory bowel disease, glycan patterns correlate with disease activity and may predict response to biologic therapies.

The mechanisms linking glycan changes to disease are diverse. Glycans influence protein-protein interactions, cell-cell communication, and immune recognition. Specific glycan structures serve as ligands for selectins, galectins, and other receptors that mediate physiological and pathological processes. Pathogens often exploit host glycans for attachment and entry, making glycan patterns relevant for infectious disease susceptibility.

Several factors contribute to variation in glycan patterns beyond disease status. Age, sex, genetics, and environmental factors all influence the glycome. Twin studies have demonstrated substantial heritability for many glycan traits, with specific genetic loci identified through GWAS. Understanding these sources of variation is important for interpreting glycomics data and developing clinical applications.

The translational potential of glycomics is increasingly being realized. Glycan biomarkers could enable earlier disease detection, more accurate prognosis, and better treatment selection. Several glycan-based tests have received regulatory approval for cancer detection and monitoring. Therapeutic glycoengineering, exemplified by efforts to optimize the glycosylation of therapeutic antibodies, represents another application of glycomics knowledge.

Future directions in glycomics include integration with other omics layers to create comprehensive molecular profiles, development of point-of-care glycan detection methods, and expansion of cohort studies to diverse populations. The emerging field of glycome editing, enabled by CRISPR-based technologies and glycosyltransferase engineering, opens new possibilities for mechanistic studies and therapeutic interventions.
DOI
10.1007/s11684-026-1250-y